To properly assess the guidance for perioperative management, we undertook a clinical epidemiology study with the primary aim of evaluating the incidence of perioperative vascular complications and their associated factors in a cohort of Japanese patients who underwent non-cardiac surgery in a tertiary medical care center. Methods: This observational study comprised two parts. In the first part, thrombotic and bleeding events and their risk factors in the perioperative period were evaluated in a total of 2,654 consecutive patients. In the second part, perioperative changes in coagulation-related factors, including the thrombin-antithrombin complex (TAT) and platelet aggregation activity, were serially characterized in 82 individuals randomly chosen from the consecutive patients. Results: The incidence of perioperative vascular complications was as follows: 1.0% for major bleeding, 0.21% for stroke and 0.21% for venous thromboembolism. No episodes of symptomatic myocardial infarction were identified in the studied population. Perioperative changes in coagulationrelated factors were found to be complex and correlated in the mixed direction of pro-and anticoagulation. The TAT values showed prolonged (across postoperative days 1-5) and prominent (＞116% increase) perioperative activation of coagulation, whereas global coagulation parameters, such as the prothrombin time, showed a tendency of anticoagulation in the immediate postoperative period. Conclusions: Our data confirm the relatively low incidence of perioperative vascular complications in the general Japanese non-cardiac surgical population. Given the delicate balance between thrombotic and bleeding events, it is important to comprehensively understand the associations between the patient's baseline risk factors and vascular complications for effective clinical management. develop thrombotic complications, such as myocardial infarction (MI), stroke, deep vein thrombosis (DVT) and pulmonary embolism (PE), in the perioperative period. Such thrombotic complications are infrequent, although they can result in significant morbidity and mortality following non-cardiac surgery, especially in patients with an advanced age and cardiovascular risk factors 1) . The incidence of complications depends on the type of surgery, comorbidities and outcomes. Major perioperative bleeding resides on the opposite 
Introduction
Patients undergoing highly invasive surgery may develop thrombotic complications, such as myocardial infarction (MI), stroke, deep vein thrombosis (DVT) and pulmonary embolism (PE), in the perioperative period. Such thrombotic complications are infrequent, although they can result in significant morbidity and mortality following non-cardiac surgery, especially in patients with an advanced age and cardiovascular risk factors 1) . The incidence of complications depends on the type of surgery, comorbidities and outcomes. Major perioperative bleeding resides on the opposite ans are consistent with those observed in Japanese remains sufficiently unanswered.
Aim
We undertook this study with the primary aim of evaluating the incidence of perioperative thrombotic and hemorrhagic complications and their associated factors in a cohort of patients who underwent non-cardiac surgery in a tertiary medical care center. Additionally, we examined perioperative changes in coagulation-related factors systematically in order to integrate clinical and laboratory evidence of postoperative hypercoagulability.
Methods

Study Population
This observational study comprised two parts, as depicted in Fig. 1 . In the first part, we assessed, by reviewing individual clinical charts, thrombotic and hemorrhagic events and their risk factors during the perioperative period in patients who underwent noncardiac surgery. In the second part, we characterized perioperative coagulation changes in a total of 82 patients (80 patients for a procoagulation and thrombosis factor analysis and 43 patients for a platelet function analysis) who were randomly chosen from the consecutive patients.
In the first part of the study, patients ≥ 20 years of age who underwent surgery under general anesthesia at the National Center for Global Health and Medicine (NCGM) Hospital were enrolled consecutively in two separate periods: from November 2009 to October 2010 (Period 1, during which 1,599 patients were prospectively enrolled) and from January 2003 to September 2003 (Period 2, during which 1,055 patients were retrospectively enrolled). In order to evaluate the potential risk of the perioperative discontinuation of aspirin and clopidogrel in patients undergoing non-cardiac surgery, we investigated Period 2, in which the rate of prescription of antiplatelet agents for the secondary prevention of cardiovascular disease was lower than that observed in Period 1 (Supplementary Table 2 ). This increased the chance of obtaining patients with some cardiovascular disease who had not taken antiplatelet agents for the secondary prevention of cardiovascular disease and who could be used as controls against those under antiplatelet therapy. Patients undergoing cardiac/vascular surgical procedures with systemic heparinization and those with underlying diseases accompanied by blood coagulation disorders were excluded from the analysis. end of the hemostatic equilibrium, increasing the risk of reoperation, the overall length of stay and hospital costs 2) . A state of hypercoagulability has long been known to develop after surgery and plays a key role in the delicate balance between thrombotic and bleeding events in the perioperative period [3] [4] [5] . This issue has drawn considerable attention in relation to the use of preoperative antiplatelet therapy, in particular, the decision to stop the administration of aspirin and clopidogrel 6, 7) . With the aging population, a substantial portion of patients undergoing non-cardiac surgery have underlying cerebro-and cardiovascular diseases and frequently take aspirin for secondary prevention. In order to properly assess the guidance for perioperative management, including the choice of surgical technique and the location and intensity of postoperative care, it is necessary to first elucidate the incidence of vascular complications after surgery.
A number of epidemiological studies, largely in populations of European descent, have investigated the incidence of thrombotic complications during the perioperative period 1, [8] [9] [10] [11] [12] , i.e. MI and stroke due to arterial thrombosis and PE and DVT due to venous thromboembolism (VTE). The reported incidence of major perioperative cardiac events (including MI) is 3.9% in patients with or at risk of cardiac disease 8) and 1.4% in relatively unselected patients 1) undergoing non-cardiac surgery, although this rate appears to largely depend on the definition adopted 9) . The incidence of perioperative stroke has also been reported to be 0.08-0.7% 10) , depending on the type of surgical procedure and patient risk factors. The incidence of VTE has been reported to be 0.63% after non-cardiac surgery 11) , with the presence of racial or ethnic variation 13, 14) . There are few data regarding the perioperative risk of bleeding in patients undergoing non-cardiac surgery; one study reported the incidence of major bleeding to be 5.4% in patients treated with orthopedic surgery 12) . In these epidemiological studies, demographic factors associated with each vascular complication have been sought in order to identify atrisk patients and institute appropriate prophylactic measures in the perioperative period.
In addition to epidemiological studies, hemostatic and coagulant factors have been evaluated perioperatively in patients undergoing non-cardiac surgery to identify biological markers reflecting thrombotic complications 5, 15) . Here, a number of studies have shown significant ethnic differences in baseline and perioperative coagulation profiles as well as the incidence of thrombotic events between Asian (including Japanese) and European populations [16] [17] [18] [19] [20] . Therefore, the question of whether previous findings in Europe-incidence of hemorrhagic complications was also assessed according to standardized bleeding definitions in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial 22) . The outcomes included stroke, ischemic heart disease, occlusion of other vessels for arterial thrombosis and PE or DVT due to VTE. The incidence of all vascular complications was documented until 30 days after surgery.
Blood Coagulation Tests
Blood samples were drawn from the peripheral vein preoperatively on the day of surgery or a few days before surgery (baseline data) and in the morning on the first, third and fifth postoperative days (PODs 1, 3 and 5). Perioperative changes in blood coagulation were monitored according to the following parameters: prothrombin time (PT), activated partial thromboplastin time (aPTT), antithrombin Ⅲ (AT), protein C activity and free protein S antigens, thrombin-antithrombin Ⅲ complex (TAT) and soluble fibrin monomer complex (SFMC).
The samples were drawn into tubes buffered with 3.13% sodium citrate. For the analysis of PT, aPTT and AT, the samples were subsequently spun at 3,500 rpm for five minutes at 5 ℃ to yield platelet-poor plasma. Aliquots of plasma were stored at 5℃ until the further analysis. Before the analysis, the samples were brought back to 37 ℃, and the PT and aPTT In addition, because stroke has been shown to occur in ~30% of subarachnoid hemorrhage (SAH) patients, principally due to vasospasm 21) , SAH patients were excluded from the analysis of thrombosis.
Ethical approval for the study was acquired from the Ethics Committee of NCGM, and written informed consent was obtained from all patients examined in the second part of the study.
Data Collection
A series of data were collected from each patient's clinical chart for the analysis. The information included: age, sex, race, height, body weight, medical history, smoking habits and operation-related information, which further included the operative procedure, emergency or elective surgery, operative time, type of anesthesia, anesthesia time, amount of bleeding during the operation, the pre-/peri-operative use of antiplatelet and/or anticoagulant agents (amount, withdrawal period before surgery and timing of resumption after surgery), the use of heparin replacement (or bridge) therapy in the perioperative period and the incidence of perioperative thrombotic and hemorrhagic complications and their time of onset. In this study, antiplatelet and/or anticoagulant agents were discontinued for a certain length of time during the perioperative period in most cases, and a portion of patients received heparin replacement therapy. The operative time and amount of bleeding. In all statistical tests, a value of P＜0.05 was considered to be significant.
Results
Incidence of Vascular Complications and Their Associated Factors
A total of 2,654 patients were consecutively enrolled from a variety of specialties in two study periods: 1,599 subjects in Period 1 and 1,055 subjects in Period 2 (Fig. 1) . Between the two study periods, while several background characteristics (i.e. age, smoking status and dyslipidemia) and operative characteristics (i.e. the anesthesia time) differed, no significant differences were found in the incidence of perioperative thrombotic or hemorrhagic complications (Supplementary Table 2 ). Therefore, in order to estimate the overall incidence of vascular complications and evaluate their associated factors, we combined the patients from the two study periods. Before the analysis of bleeding events, we excluded 270 individuals according to the exclusion criteria: 153 patients undergoing cardiac/vascular surgery with systemic heparinization, 113 patients ＜20 years of age and four patients with blood coagulation disorders. The number of patients according to specialty is shown in Supplementary Table 1. In the resultant panel of 2,384 individuals ( Table 1 and Supplementary Table  2) , 51 bleeding events (2.1%) --23 major bleeding events and 28 minor bleeding events --were detected during the follow-up (up to POD 30) period (Supplementary Table 3 ). Bleeding events tended to occur in the early postoperative period; 75% (38 of 51) of bleeding events occurred on or before POD 7. The subjects treated with emergency surgery and/or the preoperative use of anticoagulant agents appeared to exhibit an increased risk of major bleeding ( Table 1) . When compared to the corresponding control groups, the relative risk of major bleeding associated with emergency surgery and the preoperative use of anticoagulant agents was 7.02 (95% CI, 3.1-15.8; P=9.7× 10 −6
) and 21.0 (95% CI, 9.1-48.8; P = 1.8×10 −7
), respectively, in the examined cohort. An advanced age, history of cerebro-/cardiovascular disease and hypertension were associated with major bleeding. The preoperative use of anticoagulant agents was also associated with minor bleeding (Table 1) .
Before the analysis of thrombotic events, we further excluded eight individuals who did not discontinue antiplatelet agents in the perioperative period. With respect to thrombosis, 50 SAH patients were excluded from the analysis; 19 cerebral infarction cases were measured using thromboplastin and rabbit brain cephalin (reference range for PT, 70-130%; aPTT, 22.0-37.0 sec.), respectively. The AT was measured using a kinetic, functional chromogenic anti-Xa method [reference range, 80-130% of normal human plasma (NHP)]. For the analysis of the protein C activity, free protein S antigens, TAT and SFMC, the samples were spun at 3,000 rpm for 10 minutes at 5 ℃ and stored at −20 ℃, then brought back to 37 ℃ before the analysis. The protein C activity and free protein S antigen level were measured using a chromogenic substrate assay and the latex agglutination method, respectively (reference range for Protein C, 70-140% of NHP; Protein S, 60-150% of NHP). The TAT was measured using an enzyme immunosorbent assay (ELISA) method (reference range, 1.0-4.1 μg/l). The SFMC was measured using a latex turbidimetric immuno assay (reference range, ≤ 6.1 μg/ml).
Platelet Aggregation Test
The platelet aggregation test was performed using a laser-light scattering aggregometer PA-200 (Kowa Company Ltd., Tokyo, Japan). Blood samples were collected twice, once on the day of surgery or a few days before surgery (baseline data) and once in the morning on POD 1. The blood samples were carefully drawn with a 1:9 volume of 3.13% sodium citrate via venipuncture without arm squeezing, then spun at 500 rpm for 15 minutes to yield platelet-rich plasma. The aggregating agents were collagen (1.00 μg/ml), adenosine 5'-diphosphate (ADP) (2.00 μM) and epinephrine (10.00 μg/ml). The platelet aggregation activity was evaluated with a maximum aggregation rate (%MAX) 23) .
Statistics
The statistical tests were performed with the IBM SPSS ver. 21 software program (IBM Corp. Armonk, NY, USA). Student's t-test (for continuous variables) and the chi-squared test (for categorical variables) were used to compare data for the two study groups. In order to assess the strength of the relationships between the tested variables, Spearman's rank correlation coefficient was calculated along with its statistical significance.
In the assessment of risks for perioperative thrombotic complications, with regard to the perioperative discontinuation of either of two antiplatelet agents (aspirin and clopidogrel), a multivariate regression analysis and propensity score matching were performed to adjust for the following confounding factors: age, sex, present status of smoking, disease statuses of hypertension, diabetes and dyslipidemia, patients receiving prophylactic anticoagulant therapy (Supplementary Table 4) , reflecting the prothrombotic conditions of the underlying diseases. While the difference did not reach a significant level, presumably due to the small absolute number of vascular events in the present study, a history of cerebro-/cardiovascular disease and the preoperative use of antiplatelet agents tended to be prominent in the stroke cases.
Although not included in the analysis according to the exclusion criteria, three other patients were identified to have arterial thrombosis events among the 78 patients undergoing cardiac/vascular surgery with systemic heparinization but not extracorporeal circulation (see Supplementary Table 5 ). One death was observed among the patients with thrombotic events in the present study.
Management of Antiplatelet/Anticoagulant Agents in the Perioperative Period
In the initial study sample (n = 2,654), 335 individuals (13%) used antiplatelet agents preoperatively: 225 (of 335; 67%) took aspirin and 34 received the coadministration of ≥ 2 antiplatelet agents. The tim-(38% of SAH) were detected, in agreement with the results of previous studies 21) . Five arterial thrombosis and five VTE events among 2,326 individuals (0.21% each) were identified during the follow-up period ( Table 2) . Arterial thrombosis progressed to stroke in all five cases and occurred on PODs 2 and 3, except in one case, while VTE involved both PE and DVT and occurred between PODs 8 and 30, except in one case. Significant (P＜0.05) associations were observed between arterial thrombosis and an advanced age and between VTE and the amount of bleeding during surgery ( Table 1) . These associations remained significant or nearly significant (P = 0.006-0.07), even when the distinction between the study periods (Period 1 and Period 2) was adjusted for in the logistic regression model (data not shown). The Japanese guidelines for the prevention of VTE 24) were formulated in 2004, between Period 1 and Period 2 in the present study; however, there were no significant differences in the incidence of VTE between the periods (Supplementary Table 2 ). Furthermore, risk factors for VTE (i.e. age) did not appear to considerably influence its incidence, which tended to be elevated (0.7%) among the Values are means±SD unless otherwise indicated. † Exclusion criteria were: (1) patients aged ＜20 years, (2) those with some underlying diseases accompanied by blood coagulation disorder, and (3) those undergoing cardiovascular surgery with systemic heparinization. ‡ Patients who did not discontinue antiplatelet agents in the perioperative period and those with subarachnoid hemorrhage (SAH) were further excluded from the evaluation of thrombotic events. § Major bleeding was defined by ≥ 1 of the RE-LY Trial criteria (hemoglobin reduction, ≥ 2.0 g/L; blood transfusion, ≥ 2 units; symptomatic bleeding in a critical area or organ). Otherwise, the events were defined as minor bleeding. After surgery, antiplatelet agents were resumed on PODs 4-11, on average. In the case of aspirin, the timing of preoperative withdrawal and perioperative discontinuation appeared to be widely distributed, with a mean of 9.0 and 16.4 days, respectively (Fig. 2) . Only 36 (of 335) patients received perioperative bridging anticoagulation with heparin.
Among 78 individuals under the preoperative administration of warfarin, the average timing of preoperative withdrawal and postoperative resumption was 7.4 and 5.6 days, respectively, with 35 patients receiving perioperative bridging anticoagulation (Supplementary Table 6 ). Seven of 23 (30%) patients ing of the preoperative withdrawal and postoperative resumption of antiplatelet agents is summarized in Supplementary Table 6 . Overall, the timing of preoperative withdrawal in this study tended to be later than that generally recommended in guidelines. For example, in the case of aspirin, the average period was 9.0 days before surgery, and 61% of the patients discontinued the drug, in accordance with the recommended period (7-10 days) or longer. Several types of antiplatelet agents (i.e. cilostazol, sarpogrelate and dipyridamole) that are recommended to be discontinued two to three days before surgery tended to be discontinued at an earlier time in this study. The relative changes in the coagulation factors serially measured on PODs 1, 3 and 5 are shown in Fig. 3 . Downregulators of coagulation --AT, the protein C activity and free protein S antigens --all decreased considerably in the perioperative period. Harmoniously, a marker of subclinical thrombosis, TAT, considerably increased, supporting a tendency toward hypercoagulability. In contrast, although modest in fold change, the global coagulation parameters --PT-INR and aPTT --exhibited significant (P＜ 0.001) increases, i.e., a tendency toward anticoagulation ( Fig. 3 and Supplementary Table 9) , which appeared to be counterintuitive in terms of assumed hypercoagulation after surgery. Notably, the changes in blood coagulation factors were most prominent on POD 1, except for TAT, which remained significantly elevated by ＞2 fold across PODs 1-5.
The platelet aggregation activity was found to be reduced by 13-23% on POD 1 as a whole, using three aggregating agents --collagen, ADP and epinephrine (Fig. 4) ; this was also counterintuitive.
Next, we examined the correlations between perioperative changes (from baseline to the POD 1 data) in the tested coagulation-related factors (Fig. 5) . There were fair correlations between the variables reflecting similar functions, i.e. between anticoagulation indicators (PT-INR and aPTT), between downregulators of coagulation (AT, the protein C activity and free protein S antigens) and between the platelet aggregation activity levels associated with collagen, ADP and epinephrine. In particular, we observed negative correlations (r = −0.47-−0.71; P ＜0.001) between the indicators of anticoagulation and downregulators of coagulation, suggesting the possible preswho experienced major bleeding events were under the preoperative administration of warfarin (Supplementary Table 3 ).
The use of both antiplatelet and anticoagulant agents was considerably (P＜0.005) associated with risk factors for cardiovascular disease, such as male sex, an advanced age, history of cerebro-/cardiovascular disease and current smoking (Supplementary Table  7) . It has been reported that the withdrawal of aspirin and clopidogrel, but not other antiplatelet agents, potentially induces a rebound or prothrombotic effect 7) . In the present study, we found only one patient who took either aspirin or clopidogrel preoperatively among the stroke group (Table 2) . Therefore, we were unable to robustly assess the potential risk of the perioperative interruption of these two antiplatelet agents (aspirin and clopidogrel) for perioperative thrombotic complications using a multivariate regression analysis [risk ratio (RR) for perioperative stroke = 1.8 (95% CI, 0.2-19.8; P = 0.63)] or multivariate regression analysis with the propensity score for preoperative antiplatelet drug use [RR = 3.0 (95% CI, 0.2-39.6; P = 0.39)].
Perioperative Changes in Blood Coagulation and Platelet Aggregation Activity
To assess the clinical and laboratory evidence for hypercoagulability after surgery, we characterized the perioperative changes in pro-or anticoagulant factors in a subgroup of patients treated without the administration of antiplatelet/anticoagulant agents ( Fig. 1) : 80 and 43 individuals examined for blood coagulation factors and the platelet function, respectively (Supplementary Table 8 ). The distribution of the preoperative withdrawal (within 30 days before surgery; bars in light blue) and perioperative discontinuation (within 30 days before and after surgery; bars in dark blue) is shown in the figure. Not all subjects in the former counting are included in the latter counting, partly because they did not resume the agent postoperatively (see Supplementary  Table 6 ).
assess the clinical relevance, we examined the correlations between each of the coagulation-related factors and their potentially associated variables (Table 3) . There were fair correlations between the collageninduced platelet aggregation factors and the patient's age and between TAT, PT-INR and protein C and the operative (and anesthesia) time. Scatter plots showed that perioperative changes in collagen-induced platelet aggregation were positive (or more than zero) in more than half of the individuals ＞70 years of age; that is, an increase in platelet aggregation appeared to be pronounced in the elderly (Supplementary Fig. 1) . The scatter plots also showed that the correlations between perioperative TAT changes on different PODs became less prominent as time passed after surgery (Supplementary Fig. 2 ).
Discussion
Limited data are available for the incidence and risk factors of thrombotic and hemorrhagic complications in patients undergoing non-cardiac surgery (Supplementary Table 10) . In the present study, we collected outcome data for a total of 2,654 consecutive patients ≥ 20 years of age presenting for non-cardiac surgery at a single tertiary medical care center and ence of counterbalance in the immediate postoperative period. The markers of a hypercoagulable state --TAT and SFMC --did not exhibit high correlations with coagulation-related factors other than collageninduced platelet aggregation. Furthermore, in order to presumably accounting for the increased risk of thrombotic and hemorrhagic events. Of particular note is the fact that perioperative changes in platelet aggregation activity were significantly correlated with an individual patient's age and showed opposite directions on POD 1 at almost the turn of 70 years of age; i.e., these changes were increased in patients ≥ 70 years of age and decreased in those ＜70 years of age (Supplementary Fig. 1) . This phenomenon appears to account, at least in part, for the high incidence of perioperative stroke observed in the elderly patients. Among arterial thrombosis complications in the perioperative period, MI and stroke have drawn subfound the following results: 1. the incidence of perioperative stroke was 0.21% and the overall incidence of VTE (involving PE and DVT) was 0.21%, both in accordance with previously reported rates 19, 20) ; and 2. events of perioperative stroke tended to occur on or before POD 3, while those of VTE were distributed in a later phase of the postoperative period (POD 8 to POD 20). To our knowledge, this is the first study to report the recent incidence of VTE using a hospitalbased cohort design in a Japanese population. Furthermore, our data for a subgroup of patients (n= 82 in total) revealed that a series of coagulation-related factors changed dynamically in the perioperative period, The interparameter correlations were examined in 41 patients tested for both procoagulation/thrombosis factors and the platelet function (see Supplementary acute-phase reactions, such as tissue factor release from damaged vessels, inflammatory activation and compromised fibrinolysis 5) . Despite clinical and laboratory evidence of postoperative hypercoagulability, there is no sufficient description regarding the time course of coagulation changes and their dynamic regulation in patients undergoing non-cardiac surgery. Several studies have examined the ability to detect perioperative changes in various coagulation components for the purpose of assessing hypercoagulability 5, 15) . Such studies have mostly focused on the intraoperative or immediate postoperative period in a small number (n ＜30) of highly selected patients, i.e. those undergoing cardiac or vascular surgery or cholecystectomy 15, 27, 28) .
One previous study of Europeans demonstrated significant hypercoagulability beginning on POD 2 after major surgery using a combination of coagulation tests in 51 patients 5) . In the present study, we newly report that perioperative changes in coagulationrelated factors are complex and substantially correlated in the mixed direction of pro-and anticoagulation (Fig. 5) , as summarized in Supplementary Table 11 . For instance, some coagulation components (e.g., the platelet aggregation activity) are suppressed en masse in the immediate postoperative period (POD 1; Fig.  4) , while others appears to be significantly modified by a patient's age (Supplementary Fig. 1 ). In this line, it has been reported that the platelet aggregation activity continues to increase in the later postoperative period (on POD 6) 5)
. We also found that the routine coagulation parameters PT and aPTT exhibit statistically significant (P＜0.001) perioperative changes, although modest in relative changes (~11% increase, compared to the preoperative data), in the direction of anticoagulation, whereas TAT shows prolonged (across PODs 1-5) and prominent (＞116% increase) perioperative activation of coagulation ( Fig. 3 and Supplementary Table 9 ). Taken together, an integrated approach is essential for interpreting coagulationrelated hematological data, with correction for an individual patient's background and clinical manifestations.
Another issue of interest is the perioperative management of antiplatelet therapy. Recent data regarding the risk of discontinuing antiplatelet therapy in patients with coronary stents have highlighted this issue 6, 7, 29) . Among commonly-used antiplatelet drugs, aspirin and clopidogrel are particularly considered to induce a rebound or prothrombotic effect when discontinued 6, 30) . As a result, the routine withdrawal of aspirin 7-10 days before surgery, which is principally aimed at reducing the risk of bleeding complications, has been questioned 29) . In addition, little evidence has stantial attention due to their high mortality and serious disability [8] [9] [10] . It has been reported that, while the incidence of MI and stroke in the general non-cardiac surgical population is relatively low (~1.4%) 1, 10) , the prevalence of these diseases is significantly increased in subgroups of patients with or at risk for cardiovascular disease. A previous Japanese study reported that the incidence of perioperative MI and stroke is 0.33% and 0.34%, respectively, based on a 16-year longitudinal observation period 19) . Although the present study confirmed the low incidence of stroke (0.21%), the postoperative temporal distribution of the condition appears to differ between the two studies; i.e., the medial time to stroke was three days in this study (Table 2 ) compared to nine days in the previous study 19) . In agreement with the findings of previous studies 10, 19) , an advanced age (＞70 years) was found to constitute a principal risk factor for perioperative stroke ( Table 1) . On the other hand, we did not identify any perioperative MI patients in the present study. This may be due to the possibility that we missed asymptomatic MI patients, considering the previously reported high incidence of such cases 9) , as discussed below.
VTE is known to occur relatively less frequently in Japanese patients than in other ethnic groups, although there have been few reports of the epidemiology of VTE apart from questionnaire surveys 24) and literature searches 25) . Against this background, one study 20) recently reported that the incidence of VTE is 0.24% (DVT 0.19% and PE 0.05%) using a diagnosis-procedure combination database that involves administrative data for approximately 1 million surgical patients from 260 hospitals obtained between April 2008 and March 2010. Despite the similar incidence of overall VTE (0.21% in the present study), the incidence of PE (0.13%) was equivalent to or slightly higher than the reported incidence (0.05% in the entire population and 0.23% in the high-frequency group undergoing gastroenterologic or orthopedic surgery) 20) . When we focus on high-risk (cancer patients ≥ 40 years of age) and intermediate-risk (elderly patients ≥ 60 years of age) groups for VTE, the incidence remains low (0.1-0.2%) in the present study (Supplementary Table 4) . Notably, our data indicate that VTE events occur in both the early and relatively late phase (POD 8 or later) of the postoperative period. Despite the careful management of prophylaxis in the clinical setting, these findings support the need for prolonged VTE prophylaxis in at-risk surgical patients, as previously indicated 26) . The hypercoagulable state is an issue of primary interest and can be induced by surgery itself due to perioperative discontinuation of aspirin and/or clopidogrel on the incidence of perioperative thrombotic complications. However, it is likely that these effects reflect the pre-existing risk for cardiovascular disease in patients already on antiplatelet therapy as well as the risk of a rebound phenomenon. Fourth, although dynamic perioperative changes in coagulation-related factors indicate an overall tendency of hypercoagulability, the present study was not designed to correlate such hemostatic changes with thrombotic complications at the individual patient level. Further prospective studies are needed to evaluate, in a longer postoperative period, the predictive value of test variables for detecting the development of thrombotic complications.
Conclusion
Our cohort data support the relatively low incidence of perioperative thrombotic complications in the general non-cardiac surgical population of Japanese descent. Our data also suggest the need for prolonged VTE prophylaxis in at-risk surgical patients. We found that stroke and bleeding complications tend to occur in the early (until POD 7) postoperative period. Given the delicate balance between thrombotic and bleeding events during the corresponding period, it is important to understand the association between baseline risk factors and vascular complications and to integrate such knowledge with serially measured coagulation-related hematological data for effective perioperative management, although solid evidence is difficult to obtain due to the substantial complexity of the patient conditions in the postoperative period.
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